Use of brivaracetam in genetic generalized epilepsies and for acute, intravenous treatment of absence status epilepticus.
Adam StrzelczykLara KaySebastian BauerIlka ImmischKarl Martin KleinSusanne KnakeAlexander KowskiRhina KunzGerhard KurlemannLisa LangenbruchGabriel MöddelKaren Müller-SchlüterPhilipp S ReifSusanne Schubert-BastBernhard J SteinhoffIsabel SteinigLaurent M WillemsFelix von PodewilsFelix RosenowPublished in: Epilepsia (2018)
Use of BRV in GGE is well tolerated, and 50% responder rates are similar to those observed in the regulatory trials for focal epilepsies. An immediate switch from levetiracetam (LEV) to BRV at a ratio of 15:1 is feasible. The occurrence of psychobehavioral adverse events seems less prominent than under LEV, and a switch to BRV can be considered in patients with LEV-induced adverse events.